knowledge -WSS

knowledge

author：knowledge 2025-09-04 22:03:25 - browse：42

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： In Spain, a hospital brews its own CAR

WSS

Kenai launches with $82 million for Parkinson’s stem cell therapy

Obesity now affects over 1 billion people worldwide, study finds

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Three trends to watch in biotech in 2024

HCA sued by state AG for quality issues at Mission Health

Medicare drug price negotiation hasn't dried up venture capital

focus

knowledge

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Drug repurposing or repositioning? The language matters

SEC charges former device maker CEO with $41 million fraud

Sports medicine is finally prioritizing gender equality

How to keep neuroscience’s past racism from being its future

Anesthesiologist group: stop taking Ozempic before surgery

Medical device lobby: We're tired of waiting on Medicare coverage

Cancer drug shortages should be causing more outrage

What STAT readers think about the FDA and patient advocacy

Wikipedia

Prime Medicine, Myeloid Therapeutics clash over genome

In Spain, a hospital brews its own CAR

Covid isolation guidance eased by the CDC

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Carvykti CAR

Pfizer highlights cancer drugs it thinks could reignite investor interest

leisure time

focus

Wikipedia

entertainment